Visual Universitätsmedizin Mainz

German Cancer Consortium (DKTK)

The German Cancer Consortium (DKTK) was founded in 2012 to support the aim of implementing promising new cancer research findings into the clinic as quickly as possible. Therefore, seven partner locations with their research institutes and university hospitals cooperate with the German Cancer Research Center (DKFZ). The DKTK as a long-term, joint initiative involves not only the DKFZ, but also the German Federal Ministry of Education and Research (BMBF) and the participating German states.

DKTK partner-site Frankfurt/Mainz

At the DKTK partner-site Frankfurt/Mainz, the University of Frankfurt and the University Medical Center Mainz collaborate with their complementary expertise in translational cancer research. Frankfurt significantly contributes to molecularly targeted therapies. Mainz stands above all for nationally and internationally outstanding immunotherapeutic approaches, which are promoted at the UCT Mainz in close cooperation with the biotech industry and with non-university institutions. Here, TRON and the PKZI play a special role. Besides, in collaboration with the University Medical Center and the Johannes Gutenberg-University Mainz, the UCT Mainz brings further expertise, especially in the field of DNA repair research, epigenetics, and resistance development in tumor diseases, in the molecular diagnostics in early detection of cancer, and in tumor epidemiology and outcome research.

The scientists and clinicians of the DKTK partner-site Frankfurt/Mainz aim for the discovery of new cancer mechanisms (exploitation of oncogenic mechanisms), find ways to identify the importance of these mechanisms in individual patients (molecular diagnostics) to therapeutically interfere with them (drug discovery and development, molecular therapy, immunotherapy, radiation therapy), and perform clinical trials to validate these novel diagnostics and therapeutics. 

DKTK Faculty Members Mainz

Faculty Member

DKTK Program

Prof. Dr. Tobias Bopp

Cancer Immunotherapy

Prof. Dr. Peter Galle

Cancer Immunotherapy

Prof. Dr. Stephan Grabbe

Cancer Immunotherapy

Dr. Borhane Guezguez

Cancer Immunotherapy & Exploitation of Oncogenic Mechanisms

PD Dr. Thomas Kindler

Exploitation of Oncogenic Mechanisms

Prof. Dr. Krishnaraj Rajalingam

Exploitation of Oncogenic Mechanisms & Molecularly Targeted Therapy

Prof. Dr. Wilfried Roth

Molecular Diagnostics, Early Detection & Biomarker Development

Prof. Dr. Ugur Sahin

Cancer Immunotherapy & Exploitation of Oncogenic Mechanisms

Prof. Dr. Matthias Theobald

Cancer Immunotherapy

DKTK young investigator group

The DKTK Frankfurt/Mainz recruited several professorships and junior group leaders. The DKTK young investigator group in Mainz, Dr. Guezguez's group, is researching the mechanisms of stem cell self-renewal in the so-called hematopoietic niche in the bone marrow and ways in which cancer cells take advantage of these mechanisms. The goal of deciphering these mechanisms is to develop new ways of immunotherapeutic cancer treatments.

Research group Guezguez - DKTK young investigator group

School of Oncology

The School of Oncology is designed for the training of scientists and clinicians in translational oncology. In addition to a cross-disciplinary training program within the partner site Frankfurt/Mainz and the DKTK in general, junior researchers will be integrated into an active scientific community. Annual retreats and summer schools, further training seminars and workshops as well as lecture series and exchange programs, which all focus on translational oncology, will be available for the School of Oncology fellows to keep up a continuous insight into translational cancer research and clinical oncology.  

Interested in becoming a School of Oncology fellow?

If you are a clinician and haven't finished your residency yet, or if you are a scientist with medical background (up to 6 years after obtaining your doctorate), you can apply all year round by getting into contact with the  School of Oncology coordinator in Mainz.

    School of Oncology Fellows

    Bülbül
    Yagmur Bülbül
    PhD student at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Munder

    DKTK Program: Cancer Immunotherapy

    Deckert
    Stefanie Deckert
    PhD student at the Institute of Pathology - Research Group Tagscherer/Roth

    DKTK Program: Exploitation of Oncogenic mechanisms

    Dr. med. Kropp
    Dr. med. Korbinian Nepomuk Kropp
    Clinician Scientist at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Wölfel

    DKTK Program: Cancer Immunotherapy

    Lang
    Alexander Lang
    PhD student at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Echchannaoui/Hauptrock/Theobald

    DKTK Program: Cancer Immunotherapy

    Müller
    Christian Müller
    PhD student at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Echchannaoui/Hauptrock/Theobald

    DKTK Program: Cancer Immunotherapy

    Dr. rer. nat. Shah
    Dr. rer. nat. Viral Shah
    Postdoc at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Sasca

    DKTK Program: Exploitation of Oncogenic Mechanisms

    Ziegfeld
    Angelique Ziegfeld
    PhD student at the Department of Internal Medicine III - Hematology, Oncology and Pneumology - Research Group Guezguez

    DKTK Program: Cancer Immunotherapy

    DKTK Spokesperson Mainz

     

    Prof. Dr. med. Matthias Theobald
    Director of the Department of Internal Medicine III, Hematology, Oncology, and Pneumology

    Tel. 06131 17-7281
     
     E-Mail